Superluminal raises $60M to move its GPCR obesity drug into Phase 1
BVF led the round as founders Cony D'Cruz and Ajay Yekkirala prepare an oral MC4R agonist for human testing by year-end.
By RuntimeWire Staff · Published
Primary source: Superluminal Medicines
Why it matters
Superluminal has raised $213M across disclosed rounds and entered a Lilly collaboration before reaching the clinic. Phase 1 will test whether its GPCR platform can produce a differentiated medicine.
Superluminal Medicines, co-founded by CEO Cony D'Cruz and senior vice president and head of discovery Ajay Yekkirala, closed a $60 million Series B on September 3rd, 2026 to move its first drug into human testing by the end of 2026.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.